ESR1 and breast carcinoma: Next, we investigated how the estrogen receptor 1 (ESR1) agonist estradiol and the selective estrogen receptor modulators (SERMs) raloxifene and GW7604 affect proteostasis in MCF-7 breast cancer cells (Figure S4A).